Lexaria Bioscience Corp. (LEXX) Stock Forecast & Price Target
Price as of Nov 17, 2026 close · Analyst estimates retrieved Nov 18, 2026 · Source: Financial Modeling Prep (analyst estimates) (methodology)
Revenue and earnings estimates published by analysts covering Lexaria Bioscience Corp. (LEXX), and the range of their price targets. Everything on this page is a forecast made by other people — DeltaScreener does not produce estimates or targets of its own.
For Lexaria Bioscience Corp., analysts forecast revenue rising from $496,923 in 2024 to $70.19M in 2029; the average estimate for 2029 earnings per share is $20.10; 2 analysts contribute to these figures. These are forecasts published by analysts, not results.
Analyst price targets
A price target is one analyst's forecast of where a share might trade, usually over twelve months. Targets are frequently revised, they disagree with each other, and they are not a measure of what a company is worth.
Revenue forecast (USD)
The spread between low and high is how far analysts disagree, which is usually a better guide than the average alone.
Earnings per share forecast
Lexaria Bioscience Corp. (LEXX) forecast — frequently asked questions
What is the analyst price target for Lexaria Bioscience Corp.?
Analysts covering Lexaria Bioscience Corp. (LEXX) have a consensus price target of $1.50, 64.1% below the current price of $4.18. Published targets range from $1.50 to $1.50. A price target is a forecast, not a measure of value, and targets are revised often.
What are analysts forecasting for Lexaria Bioscience Corp.'s earnings?
The average analyst estimate for Lexaria Bioscience Corp. (LEXX) earnings per share in 2029 is 20.10, with individual estimates between 20.10 and 20.10.
How much revenue is Lexaria Bioscience Corp. expected to make?
Analysts forecast Lexaria Bioscience Corp. (LEXX) revenue of $70.19M in 2029, based on 1 published estimates.
How many analysts cover LEXX?
2 analysts contribute estimates for Lexaria Bioscience Corp. (LEXX). Thin coverage makes an average less reliable.
Analyst forecasts for other Biotechnology stocks
Popular Stocks
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.